BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 23494965)

  • 1. The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms.
    Tadmor T; Bejar J; Attias D; Mischenko E; Sabo E; Neufeld G; Vadasz Z
    Am J Hematol; 2013 May; 88(5):355-8. PubMed ID: 23494965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of beta-catenin in chronic myeloproliferative disorders.
    Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
    Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
    Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
    FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasms.
    Medinger M; Tzankov A; Kern J; Pircher A; Hermann M; Ott HW; Gastl G; Untergasser G; Gunsilius E
    Thromb Haemost; 2011 Jan; 105(1):72-80. PubMed ID: 20978717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow biopsy (BMB). II. Bone marrow biopsy in myeloproliferative disorders.
    Macavei I; Galatâr N
    Morphol Embryol (Bucur); 1989; 35(2):117-27. PubMed ID: 2529429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
    Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
    Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GATA1 downregulation in prefibrotic and fibrotic stages of primary myelofibrosis and in the myelofibrotic progression of other myeloproliferative neoplasms.
    Sangiorgio VFI; Nam A; Chen Z; Orazi A; Tam W
    Leuk Res; 2021 Jan; 100():106495. PubMed ID: 33360878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
    Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
    J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis.
    Rambaldi B; Diral E; Donsante S; Di Marzo N; Mottadelli F; Cardinale L; Dander E; Isimbaldi G; Pioltelli P; Biondi A; Riminucci M; D'Amico G; Elli EM; Pievani A; Serafini M
    Ann Hematol; 2021 Jan; 100(1):105-116. PubMed ID: 33089365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myelofibrosis--what's in a name? Consensus on definition and EUMNET grading.
    Thiele J; Kvasnicka HM
    Pathobiology; 2007; 74(2):89-96. PubMed ID: 17587880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombopoietin receptor (Mpl) expression by megakaryocytes in myeloproliferative disorders.
    Bock O; Schlué J; Mengel M; Büsche G; Serinsöz E; Kreipe H
    J Pathol; 2004 May; 203(1):609-15. PubMed ID: 15095485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients.
    Ruberti S; Bianchi E; Guglielmelli P; Rontauroli S; Barbieri G; Tavernari L; Fanelli T; Norfo R; Pennucci V; Fattori GC; Mannarelli C; Bartalucci N; Mora B; Elli L; Avanzini MA; Rossi C; Salmoiraghi S; Zini R; Salati S; Prudente Z; Rosti V; Passamonti F; Rambaldi A; Ferrari S; Tagliafico E; Vannucchi AM; Manfredini R
    Leukemia; 2018 Feb; 32(2):438-449. PubMed ID: 28745329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Utility of bone marrow biopsy in the diagnosis of myeloproliferative neoplasm].
    Tovar-Bobadilla JL; Ortiz-Hidalgo C
    Gac Med Mex; 2016; 152(3):407-18. PubMed ID: 27335198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA expression and JAK2 allele burden in bone marrow trephine biopsies of polycythemia vera, essential thrombocythemia and early primary myelofibrosis.
    Gebauer N; Bernard V; Gebauer W; Feller AC; Merz H
    Acta Haematol; 2013; 129(4):251-6. PubMed ID: 23343777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2.
    Vadasz Z; Kessler O; Akiri G; Gengrinovitch S; Kagan HM; Baruch Y; Izhak OB; Neufeld G
    J Hepatol; 2005 Sep; 43(3):499-507. PubMed ID: 16023247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mast cell burden and reticulin fibrosis in the myeloproliferative neoplasms: a computer-assisted image analysis study.
    Ahmed A; Powers MP; Youker KA; Rice L; Ewton A; Dunphy CH; Chang CC
    Pathol Res Pract; 2009; 205(9):634-8. PubMed ID: 19446406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.
    Risum M; Madelung A; Bondo H; Bzorek M; Kristensen MH; Stamp IM; Hasselbalch HC
    APMIS; 2011 Aug; 119(8):498-504. PubMed ID: 21749449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrophage frequency in the bone marrow correlates with morphologic subtype of myeloproliferative neoplasm.
    Molitor DCA; Boor P; Buness A; Schneider RK; Teichmann LL; Körber RM; Horvath GL; Koschmieder S; Gütgemann I
    Ann Hematol; 2021 Jan; 100(1):97-104. PubMed ID: 33104881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of vascular endothelial growth factor receptor 1 correlates with VEGF and microvessel density in Philadelphia chromosome-negative myeloproliferative neoplasms.
    Boiocchi L; Vener C; Savi F; Bonoldi E; Moro A; Fracchiolla NS; Iurlo A; Deliliers GL; Coggi G; Bosari S; Gianelli U
    J Clin Pathol; 2011 Mar; 64(3):226-31. PubMed ID: 21217153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.